We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Glulisine + Lantus in Type I Patients

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: October 19, 2007
Last Update Posted: June 15, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
To evaluate the efficacy (in terms of change HbA1c from baseline to endpoint) and safety (in terms of adverse events, clinical chemistry, lipids, hematology) of insulin glulisine (HMR 1964) in subjects with type I diabetes mellitus To evaluate the change in HbA1c at week 26, blood/glucose parameters, hypoglycemia, insulin dose in subjects with type I diabetes mellitus receiving HMR 1964 and insulin glargine.

Condition Intervention Phase
Diabetes Mellitus, Type 1 Drug: Insuline Glulisine Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Multicenter, Open, Non-Randomised Phase III Clinical Study of Efficacy and Safety of Insulin Glulisine (HMR1964) Injected Subcutaneously in Patients With Type 1 Diabetes Mellitus Using Also Insulin Glargine During 26 Weeks of Therapy

Resource links provided by NLM:

Further study details as provided by Sanofi:

Primary Outcome Measures:
  • Change of HbA1c. [ Time Frame: from baseline to endpoint. ]

Secondary Outcome Measures:
  • Change in HbA1c. [ Time Frame: from baseline (week 1) to weeks 12 and 26 ]
  • Blood glucose parameters, hypoglycaemic episodes and dosage of the mealtime and basal insulins. [ Time Frame: from baseline to endpoint. ]

Enrollment: 142
Study Start Date: September 2004
Study Completion Date: February 2005
Primary Completion Date: February 2005 (Final data collection date for primary outcome measure)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adult men and women (>18 years) with type I diabetes mellitus (onset of diabetes under the age of 40)
  • An HbA1c range of >6.5 - <11%
  • And on multiple injection regimen (more than 1 year of continuous insulin treatment)
  • Body mass index <35.

Exclusion Criteria:

  • Active proliferative diabetic retinopathy
  • Diabetes other than type I diabetes mellitus
  • Pancreatectomised subjects
  • Subjects who have undergone pancreas and or islet cell transplantats, requiring treatment with not permited drugs during the study, previous treatment (in the period not less than 1 month before the beginning of the trial) with insulin glargine
  • Hypersensitivity to insulin
  • Major systemic diseases
  • Impaired hepatic or renal function

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00546702

Russian Federation
Moscow, Russian Federation
Sponsors and Collaborators
Study Director: Olga Efremenkova Sanofi
  More Information

Responsible Party: Medical Affairs Study Director, sanofi-aventis
ClinicalTrials.gov Identifier: NCT00546702     History of Changes
Other Study ID Numbers: HMR1964A_3505
First Submitted: October 18, 2007
First Posted: October 19, 2007
Last Update Posted: June 15, 2009
Last Verified: June 2009

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases